Download PDF
Laryngorhinootologie 2007; 86(5): 384-393
DOI: 10.1055/s-2007-966390
CME-Fortbildung

© Georg Thieme Verlag KG Stuttgart · New York

Mitomycin C und Wundheilung

Mitomycin C in Head and Neck Surgical ProceduresM.  O.  Scheithauer1 , H.  Riechelmann1
  • 1HNO-Universitätsklinik und Poliklinik Ulm (Ärztlicher Direktor: Prof. Dr. G. Rettinger)
Further Information

Publication History

Publication Date:
09 May 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Mitomycin C (MMC) wird in der Onkologie als Chemotherapeutikum verwendet. Seine Metaboliten binden an DNA-Moleküle und induzieren DNA-Quervernetzungen. MMC interferiert so mit der DNA-, RNA- und Proteinsynthese. Hierdurch hemmt MMC das Wachstum und die Teilung von Fibroblasten, den Schlüsselzellen von Wundheilung und Narbenbildung. Als Besonderheit hemmt MMC insbesondere die Synthese von Proteinen der Zellzwischensubstanz wie Fibronektin und Kollagen, die im Rahmen der Wundheilung wesentliche Funktionen ausüben. Aufgrund dieser Eigenschaften ist MMC grundsätzlich in der Lage, die Bildung von übermäßigen Narben, Adhäsionen, Synechien und Restenosierungen nach Eingriffen im Kopf-Hals-Bereich zu reduzieren. In folgendem Fortbildungsbeitrag werden die Ergebnisse experimenteller und klinischer Untersuchungen zur topischen Anwendung von MMC berichtet.

Abstract

Mitomycin C (MMC) is frequently used in combination chemotherapy. Its metabolites bind to DNA-molecules and causes DNA crosslinking, which interferes with the synthesis of DNA, RNA and proteins. MMC is thus able to reduce fibroblast proliferation. Moreover, MMC particularly inhibits the synthesis of extracellular matrix proteins including fibronectin and various collagens. These properties have been demonstrated in several experimental studies. Beside its merits in treatment of malignancies, MMC may thus be useful to prevent hypertrophic scars and keloids, adhesions and ostial restenosis following head and neck surgical procedures. Clinically, MMC has been applied to prevent scarring after ophthalmologic surgery. Recent experimental and clinical trials investigating the effects of MMC on wound healing following head and neck surgical procedures are reviewed.

Schlüsselwörter

Wundheilung - Nasennebenhöhlenchirurgie - Mitomycin C - Narben - Stenosen - Adhäsionen

Key words

sinus surgery - mitomycin C - wound healing - scarring - stenosis - adhesions

Literatur

  • 1 Scheithauer M, Riechelmann H. Übersicht Teil I: Grundlagen der kutanen Wundheilung.  Laryngo Rhino Otol. 2003;  82 31-35
    PubMedGoogle Scholar
  • 2 Scheithauer M, Riechelmann H. Übersicht Teil II: Die gestörte kutane Wundheilung.  Laryngo Rhino Otol. 2003;  82 36-39
    PubMedGoogle Scholar
  • 3 Cummings J, Spanswick V J, Smyth J F. Re-evaluation of the molecular pharmacology of mitomycin C.  Eur J Cancer. 1995;  31A 1928-1933
    PubMedGoogle Scholar
  • 4 Chen T, Kunnavatana S S, Koch R J. Effects of mitomycin-C on normal dermal fibroblasts.  Laryngoscope. 2006;  116 514-517
    CrossrefPubMedGoogle Scholar
  • 5 Rahal A, Peloquin L, Ahmarani C. Mitomycin C in sinus surgery: preliminary results in a rabbit model.  J Otolaryngol. 2001;  30 1-5
    CrossrefPubMedGoogle Scholar
  • 6 Ferguson B, Gray S D, Thibeault S. Time and dose effects of mitomycin C on extracellular matrix fibroblasts and proteins.  Laryngoscope. 2005;  115 110-115
    CrossrefPubMedGoogle Scholar
  • 7 Porter G T, Gadre S A, Calhoun K H. The effects of intradermal and topical mitomycin C on wound healing.  Otolaryngol Head Neck Surg. 2006;  135 56-60
    CrossrefPubMedGoogle Scholar
  • 8 Gray S D, Tritle N, Li W. The effect of mitomycin on extracellular matrix proteins in a rat wound model.  Laryngoscope. 2003;  113 237-242
    CrossrefPubMedGoogle Scholar
  • 9 Ribeiro F A, Guaraldo L, Borges J P, Zacchi F F, Eckley C A. Clinical and histological healing of surgical wounds treated with mitomycin C.  Laryngoscope. 2004;  114 148-152
    CrossrefPubMedGoogle Scholar
  • 10 Sewall G K, Robertson K M, Connor N P, Heisey D M, Hartig G K. Effect of topical mitomycin on skin wound contraction.  Arch Facial Plast Surg. 2003;  5 59-62
    PubMedGoogle Scholar
  • 11 Stewart C E, Kim J Y. Application of mitomycin-C for head and neck keloids.  Otolaryngol Head Neck Surg. 2006;  135 946-950
    CrossrefPubMedGoogle Scholar
  • 12 Talmi Y P, Orenstein A, Wolf M, Kronenberg J. Use of mitomycin C for treatment of keloid: a preliminary report.  Otolaryngol Head Neck Surg. 2005;  132 598-601
    CrossrefPubMedGoogle Scholar
  • 13 Sanders K W, Gage-White L, Stucker F J. Topical mitomycin C in the prevention of keloid scar recurrence.  Arch Facial Plast Surg. 2005;  7 172-175
    CrossrefPubMedGoogle Scholar
  • 14 Singh G, Wilson M R, Foster C S. Mitomycin eye drops as treatment for pterygium.  Ophthalmology. 1988;  95 813-821
    PubMedGoogle Scholar
  • 15 Chen C W, Huang H T, Bair J S, Lee C C. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma.  J Ocul Pharmacol. 1990;  6 175-182
    PubMedGoogle Scholar
  • 16 Eliashar R, Eliachar I, Esclamado R, Gramlich T, Strome M. Can topical mitomycin prevent laryngotracheal stenosis?.  Laryngoscope. 1999;  109 1594-1600
    PubMedGoogle Scholar
  • 17 Simpson C B, James J C. The efficacy of mitomycin-C in the treatment of laryngotracheal stenosis.  Laryngoscope. 2006;  116 1923-1925
    CrossrefPubMedGoogle Scholar
  • 18 Rahbar R, Valdez T A, Shapshay S M. Preliminary results of intraoperative mitomycin-C in the treatment and prevention of glottic and subglottic stenosis.  J Voice. 2000;  14 282-286
    CrossrefPubMedGoogle Scholar
  • 19 Rahbar R, Shapshay S M, Healy G B. Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.  Ann Otol Rhinol Laryngol. 2001;  110 1-6
    PubMedGoogle Scholar
  • 20 Rahbar R, Jones D T, Nuss R C, Roberson D W, Kenna M A, McGill T J, Healy G B. The role of mitomycin in the prevention and treatment of scar formation in the pediatric aerodigestive tract: friend or foe?.  Arch Otolaryngol Head Neck Surg. 2002;  128 401-406
    PubMedGoogle Scholar
  • 21 Hartnick C J, Hartley B E, Lacy P D, Liu J, Bean J A, Willging J P, Myer C M3, Cotton R T. Topical mitomycin application after laryngotracheal reconstruction: a randomized, double-blind, placebo-controlled trial.  Arch Otolaryngol Head Neck Surg. 2001;  127 1260-1264
    PubMedGoogle Scholar
  • 22 Hueman E M, Simpson C B. Airway complications from topical mitomycin C.  Otolaryngol Head Neck Surg. 2005;  133 831-835
    CrossrefPubMedGoogle Scholar
  • 23 Rombaux P, de Toeuf C, Hamoir M, Eloy P, Bertrand B, Veykemans F. Transnasal repair of unilateral choanal atresia.  Rhinology. 2003;  41 31-36
    PubMedGoogle Scholar
  • 24 Prasad M, Ward R F, April M M, Bent J P, Froehlich P. Topical mitomycin as an adjunct to choanal atresia repair.  Arch Otolaryngol Head Neck Surg. 2002;  128 398-400
    PubMedGoogle Scholar
  • 25 You Y A, Fang C T. Intraoperative mitomycin C in dacryocystorhinostomy.  Ophthal Plast Reconstr Surg. 2001;  17 115-119
    PubMedGoogle Scholar
  • 26 Roozitalab M H, Amirahmadi M, Namazi M R. Results of the application of intraoperative mitomycin C in dacryocystorhinostomy.  Eur J Ophthalmol. 2004;  14 461-463
    PubMedGoogle Scholar
  • 27 Estrem S A, Batra P S. Preventing myringotomy closure with topical mitomycin C in rats.  Otolaryngol Head Neck Surg. 1999;  120 794-798
    CrossrefPubMedGoogle Scholar
  • 28 Estrem S A, Vanleeuwen R N. Use of mitomycin C for maintaining myringotomy patency.  Otolaryngol Head Neck Surg. 2000;  122 8-10
    CrossrefPubMedGoogle Scholar
  • 29 Jassir D, Buchman C A, Gomez-Marin O. Safety and efficacy of topical mitomycin C in myringotomy patency.  Otolaryngol Head Neck Surg. 2001;  124 368-373
    CrossrefPubMedGoogle Scholar
  • 30 Jassir D, Odabasi O, Gomez-Marin O, Buchman C A. Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure.  Otolaryngol Head Neck Surg. 2003;  129 471-474
    CrossrefPubMedGoogle Scholar
  • 31 Babu S C, Kartush J M, Patni A. Otologic effects of topical mitomycin C: phase I-evaluation of ototoxicity.  Otol Neurotol. 2005;  26 140-144
    CrossrefPubMedGoogle Scholar
  • 32 Ragab S M. The effect of radiofrequency and mitomycin C on the closure rate of human tympanostomy.  Otol Neurotol. 2005;  26 355-360
    CrossrefPubMedGoogle Scholar
  • 33 Banthia V, Selesnick S H. Mitomycin-C in the postsurgical ear canal.  Otolaryngol Head Neck Surg. 2003;  128 882-886
    CrossrefPubMedGoogle Scholar
  • 34 Battelino S, Hocevar-Boltezar I, Zargi M. Intraoperative use of mitomycin C in fibrous atresia of the external auditory canal.  Ear Nose Throat J. 2005;  84 776-779
    PubMedGoogle Scholar
  • 35 Hosemann W. Die endonasale Chirurgie der Nasennebenhöhlen - Konzepte, Techniken, Ergebnisse, Komplikationen, Revisionseingriffe.  Eur Arch Otorhinolaryngol Suppl. 1996;  1 155-269
    PubMedGoogle Scholar
  • 36 Ramadan H H. Surgical causes of failure in endoscopic sinus surgery.  Laryngoscope. 1999;  109 27-29
    CrossrefPubMedGoogle Scholar
  • 37 Weber R, Mai R, Hosemann W, Draf W, Toffel P. The success of 6-month stenting in endonasal frontal sinus surgery.  Ear Nose Throat J. 2000;  79 930-938
    PubMedGoogle Scholar
  • 38 Rajapaksa S P, Ananda A, Cain T M, Oates L, Wormald P J. Frontal ostium neo-osteogenesis and restenosis after modified endoscopic Lothrop procedure in an animal model.  Clin Otolaryngol Allied Sci. 2004;  29 386-388
    PubMedGoogle Scholar
  • 39 Kark L R, Karp J M, Davies J E. Platelet releasate increases the proliferation and migration of bone marrow-derived cells cultured under osteogenic conditions.  Clin Oral Implants Res. 2006;  17 321-327
    CrossrefPubMedGoogle Scholar
  • 40 Hu D, Sires B S, Tong D C, Royack G A, Oda D. Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts.  Ophthal Plast Reconstr Surg. 2000;  16 119-125
    CrossrefPubMedGoogle Scholar
  • 41 Ingrams D R, Volk M S, Biesman B S, Pankratov M M, Shapshay S M. Sinus surgery: does mitomycin C reduce stenosis?.  Laryngoscope. 1998;  108 883-886
    CrossrefPubMedGoogle Scholar
  • 42 Park S W, Koo B S, Park Y H, Jin Y D, Rha K S. Effect of topical mitomycin C for antrostomy in rabbit with sinusitis.  Eur Arch Otorhinolaryngol. 2006;  263 917-923
    CrossrefPubMedGoogle Scholar
  • 43 Amonoo-Kuofi K, Lund V J, Andrews P, Howard D J. The role of mitomycin C in surgery of the frontonasal recess: a prospective open pilot study.  Am J Rhinol. 2006;  20 591-594
    CrossrefPubMedGoogle Scholar
  • 44 Chung J H, Cosenza M J, Rahbar R, Metson R B. Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study.  Otolaryngol Head Neck Surg. 2002;  126 468-474
    CrossrefPubMedGoogle Scholar
  • 45 Kim S T, Gang I G, Cha H E, Ha J S, Chung Y S. Effect of mitomycin C on the size of antrostomy after endoscopic sinus surgery.  Ann Otol Rhinol Laryngol. 2006;  115 673-678
    CrossrefPubMedGoogle Scholar
  • 46 Anand V K, Tabaee A, Kacker A, Newman J G, Huang C. The role of mitomycin C in preventing synechia and stenosis after endoscopic sinus surgery.  Am J Rhinol. 2004;  18 311-314
    PubMedGoogle Scholar

Dr. M. O. Scheithauer

HNO-Universitätsklinik und Poliklinik Ulm (Ärztl. Direktor: Prof. Dr. G. Rettinger)

Frauensteige 12

89075 Ulm

Email: marc.scheithauer@uniklinikulm.de

      >